George,
Sure that 100M is enough for ABGX work, on AZ's targets. Usually, bios develop this on their own, and than sell to pharma, big bucks. 36 targets is big number, the biggest the number the less likely something is near term. For current ABGX, this is good deal (good partner and field covered with future works), but my question is COULD ABGX do better? Can they generate targets with CRGN, invest their own money and generate higher profit down the road?
W was talking (few months back) about 50-50 deal for early stage candidates-programs. This is not one of them. Are they short on cash, and manufacturing start-up is consuming more $$$ than they projected? I guess so. So, somewhere else cats were necessity. That is what I do not like. IF there is serious PROGRESS with ABX-EGF Mr. Market would be generous with cash infusion, and ABGX would be able to do many things on their own. We known that MLNM APETITE and PRIDE were TOO BIG, and they paid price. ABGX do not need to have MLNM appetite, but to generate profitable company they NEED drugs on its own. Not 5-10% royalty stream, imo.
Miljenko
PS: I am not that negative on ABGX, only trying to point that risk did increase recently, jimho. |
